BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  MediciNova Announces the Presentation of Additional Positive Top-Line Results from the SPRINT-MS Phase IIb Trial of MN-166 (ibudilast) in Progressive MS

  The drug achieved a statistically significant 48% reduction in whole brain atrophy with a favorable safety and tolerability profile.

  October 30, 2017

   · 

  10 min read
• Trading of Össur Shares to be Concentrated on Nasdaq Copenhagen From 6 December 2017

  By concentrating the trading on one market, trading liquidity of Össur shares will increase and the price formation will be more effective for the benefit of all shareholders.

  October 30, 2017

   · 

  2 min read
• Drug Development

  Global Blood Therapeutics Announces Presentation of Case Study Demonstrating Positive Effect of Voxelotor (GBT440) in a Sickle Cell Disease Patient With Severe and Symptomatic Anemia

  The patient received the investigational agent through single-patient compassionate access.

  October 30, 2017

   · 

  8 min read
• Drug Development

  Kura Oncology Development Candidate KO-539 Shows Robust Preclinical Anti-Tumor Activity in NPM1- and DNMT3A-Mutant AML

  The results were featured in a late-breaking presentation today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia.

  October 30, 2017

   · 

  4 min read
• 

  Drug Development

  Novartis PARADIGMS Data Show Children And Adolescents With MS Had an 82% Lower Relapse Rate With Gilenya Vs. Interferon Beta-1a

  Treatment with oral Gilenya resulted in an 82% reduction in the rate of relapses (annualized relapse rate) over a period of up to two years.

  October 30, 2017

   · 

  13 min read
• 

  Drug Development

  Novartis to Present First of Its Kind Evidence For Cosentyx on Potential to Maintain Mobility in Patients With AS and PsA

  The new Cosentyx data will be presented at the 2017 ACR/ARHP annual meeting next month.

  October 30, 2017

   · 

  12 min read
• Business

  MDxhealth Enters Into Distribution Agreement With Unilabs for SelectMDx for Prostate Cancer

  Under the deal,, Unilabs medical laboratory in Geneva Switzerland, will perform SelectMDx service testing for all its clinical labs in France, Portugal and more.

  October 30, 2017

   · 

  4 min read
• 

  Deals

  Ablynx Closes $200M IPO in the United States

  The net proceeds are estimated at $182.3 million.

  October 30, 2017

   · 

  7 min read
• HyperMed Imaging Announces Cardiology Group as Early Adopter For Its New HyperView Product

  The HyperView is a fast, handheld, battery operated, non-invasive and portable diagnostic imaging device that is used to assess tissue oxygenation without contacting the patient and without the need for injectable contrast.

  October 30, 2017

   · 

  3 min read
• Surgical Science Release: Lapsim Essence, A VR Simulator Offered As A Subscription Service, Now Ready for Delivery

  Virtual reality simulation has shown to deliver an effective and patient‐safe route to technical competence in the operating room.

  October 30, 2017

   · 

  1 min read